Trevena's TRV027 Included In Global COVID-19 Study

Trevena Inc TRVN has announced that its novel AT1 receptor-selective agonist, TRV027, has been selected for inclusion in an international Phase 2-Phase 3 trial in COVID-19 patients.
The trial is being conducted and funded as part of REMAP-CAP, a global network of clinicians, institutions, and research facilities to evaluate treatments with the potential to reduce mortality, ICU use, and morbidity in severely ill patients with COVID-19.
Four active treatments are included in the study protocol, including TRV027, with 200-300 patients expected to be enrolled in each arm. TRV027 will be administered in conjunction with an ACE inhibitor.
The primary outcome is a composite of in-hospital mortality and provision of organ failure support while admitted to an ICU in the 21 days following randomization.
The trial is also evaluating clinical outcomes, including ICU and hospital length of stay, ventilator-free days, and organ failure-free days.
Price Action: TRVN shares are up 2.94% at $1.75 in the premarket session on the last check Wednesday.